ABL202: A Novel Antibody-Drug Conjugate Targeting ROR1-Expressing Tumors

Time: 1:30 pm


  • Examine ROR1; An attracting cancer target that expresses in various cancer including CLL, TNBC, and lung cancer
  • Assess the activity of anti-ROR1 ADC that was tested on various xenograft models
  • Some preclinical results will be presented for further discussion